Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group
| Autor: | Massimo Del Gaudio, Francesco Lupo, Paolo De Simone, Stefano Fagiuoli, Luciano De Carlis, Umberto Cillo, Riccardo Volpes, Giuseppe Tisone |
|---|---|
| Přispěvatelé: | Cillo, U, De Carlis, L, Del Gaudio, M, De Simone, P, Fagiuoli, S, Lupo, F, Tisone, G, Volpes, R |
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Carcinoma Hepatocellular Consensus mTOR inhibitor Hepatocellular carcinoma medicine.medical_treatment Population MEDLINE Guidelines 030230 surgery Liver transplantation Tacrolimus 03 medical and health sciences Consensus recommendation 0302 clinical medicine Calcineurin inhibitor Chronic kidney disease Internal medicine medicine Humans Sirolimu Consensus recommendations Everolimus Intensive care medicine education Sirolimus education.field_of_study Hepatology business.industry Liver Neoplasms Correction Immunosuppression Transplant Recipients Liver Transplantation Transplantation Everolimu Italy Tacrolimu Solid-organ transplantation 030211 gastroenterology & hepatology business Immunosuppressive Agents medicine.drug |
| Zdroj: | Hepatol Int Hepatology International |
| ISSN: | 1936-0541 1936-0533 |
| Popis: | It is a well-recognized fact that implementing new guidelines in clinical practice may be difficult; therefore the Italian Society for Organ and Tissue Transplantation (SITO) set out to define practical immunosuppression tools for the management of liver transplantation patients. In 2017, an Italian Working Group of liver transplant experts and hepatologists issued a set of consensus statements along with evidence-based recommendations on the use of everolimus after liver transplantation. This article presents the evidence- and consensus-based algorithms developed within the Italian Working Group, which are aimed towards guiding clinicians in the selection of immunosuppressive regimens for the management of adult liver transplant recipients in real-life practice. The liver transplant recipient population, typically managed in clinical practice, was divided into the following categories: (1) standard patients; (2) critically ill patients; (3) patients with a specific etiology; (4) patients with hepatocellular carcinoma; (5) and patients with de novo malignancies. The algorithms are divided into two parts, according to the time from transplantation (0–3 months and > 3 months) and are discussed here along with relevant supporting literature, when available. Ultimately, it is hoped that the evidence- and consensus-based algorithms developed within the Italian Working Group, and presented here, contribute to simplify, personalize, and optimize immunosuppression of liver transplantation recipients in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink